Perception Neuroscience Company Profile - aVenture Research
Perception Neuroscience
Perception Neuroscience is a clinical-stage company whose glutamatergic drug R-ketamine (PCN-101) completed a Phase 1 study for treatment-resistant depression.
Perception Neuroscience's lead development product is R-ketamine (PCN-101), a glutamatergic modulator that it has studied in patients with treatment-resistant depression. The company holds an exclusive license to this intellectual property and has completed a Phase 1 multiple ascending dose study in healthy volunteers. ATAI Life Sciences acquired a majority stake in Perception Neuroscience and describes it as a biopharmaceutical company.
It has initiated a Phase 2a proof-of-concept study in patients with treatment-resistant depression, its target customer. The company partnered with Otsuka Pharmaceuticals to develop PCN-101 in Japan. New rapid-acting antidepressant drugs are expected to be more efficacious than approved antidepressants that often take weeks to achieve maximal effectiveness.